Page last updated: 2024-12-06

moxalactam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Moxalactam: Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

moxalactam : A broad-spectrum oxacephem antibiotic in which the oxazine ring is substituted with a tetrazolylthiomethyl group and the azetidinone ring carries methoxy and 2-carboxy-2-(4-hydroxyphenyl)acetamido substituents. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID47499
CHEMBL ID74632
CHEBI ID599928
SCHEMBL ID194012
MeSH IDM0014142

Synonyms (76)

Synonym
DIVK1C_000909
KBIO1_000909
(6r,7r)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-(methyloxy)-3-{[(1-methyl-1h-tetrazol-5-yl)thio]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
latamoxef [inn:ban]
5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-
latamoxefum [inn-latin]
einecs 265-287-9
oxa-cephem
SPECTRUM_000971
SMP1_000200
BSPBIO_002039
IDI1_000909
moxalactam
64952-97-2
latamoxef
C07231
(6r,7r)-7-[[3-hydroxy-2-(4-hydroxyphenyl)-3-oxo-propanoyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[carboxy(4-hydroxyphenyl)acetyl]amino]-7methoxy-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-8-oxo-
DB04570
festamoxin
lamoxactam
lmox
KBIO2_001451
KBIO3_001539
KBIOSS_001451
KBIO2_004019
KBIOGR_000587
KBIO2_006587
SPECTRUM4_000064
SPBIO_001054
SPECTRUM2_001067
PRESTWICK1_000819
NINDS_000909
PRESTWICK0_000819
SPBIO_002638
SPECTRUM3_000510
SPECTRUM5_001371
PRESTWICK2_000819
CHEMBL74632
latamoxef (inn)
D08109
(6r,7r)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-methoxy-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CHEBI:599928 ,
latamoxefum
(6r-(6alpha,7alpha,7(s*)))-7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
79120-38-0
5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-(6alpha,7alpha,7(s*)))-
7beta-(2-carboxy-2-(4-hydroxyphenyl)acetamido)-7alpha-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-1-oxa-1-dethia-3-cephem-4-carboxylic acid
7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid (6r-(6alpha,7alpha,7(s*)))-
bdbm50370589
unii-vuf6c936z3
vuf6c936z3 ,
EPITOPE ID:180870
latamoxef [inn]
moxalactam [vandf]
latamoxef [who-dd]
latamoxef [jan]
5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r,7r)-
(6r,7r)-7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
moxalactam [mi]
SCHEMBL194012
(6r,7r)-7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
listeria mox supplement
DTXSID9023338
(6r,7r)-7-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7-methoxy-3-{[(1-methyl-1h-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
moxalactam supplement, for microbiology
SBI-0051450.P003
(6r,7r)-7-(2-carboxy-2-(4-hydroxyphenyl)acetamido)-7-methoxy-3-((1-methyl-1h-tetrazol-5-ylthio)methyl)-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Q3827439
BCP12584
5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2r)-carboxy(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-8-oxo-,(6r,7r)-
64952-97-2 (free acid)
A867780
moxalactamsupplement
EN300-19651960
gtpl12031

Research Excerpts

Overview

Moxalactam appears to be an effective antibiotic for the treatment of neonatal gram-negative bacillary meningitis. It is a beta-lactamase inactivator and inactivates most of the cephalosporinases produced by gram- negative bacteria.

ExcerptReferenceRelevance
"Moxalactam is a new 1-oxa-beta-lactam antibiotic that is similar in many respects to the third-generation cephalosporins. "( New drug evaluations: moxalactam (Moxam, Eli Lilly).
Polk, RE, 1982
)
2.02
"Moxalactam appears to be an effective antibiotic for the treatment of neonatal gram-negative bacillary meningitis."( Successful moxalactam therapy for gram-negative bacillary meningitis in neonates.
Denson, S; Kaplan, SL; Mason, EO; Pickering, LK; Ramos, OM, 1982
)
1.38
"Moxalactam is a new cephalosporin with a broad spectrum of activity which includes Pseudomonas aeruginosa in addition to Klebsiella species Escherichia coli, and Staphylococcus aureus. "( Empiric antibiotic therapy for suspected infection in granulocytopenic cancer patients: a comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin.
De Jongh, CA; Finley, RS; Fortner, CL; Moody, MR; Newman, KA; Salvatore, PC; Schimpff, SC; Standiford, HC; Wade, JC; Wiernik, PH, 1982
)
1.91
"Moxalactam disodium is a new broad-spectrum antibiotic structurally related to the cephalosporins. "( Moxalactam therapy. Its use in chronic suppurative otitis media and malignant external otitis.
Caparosa, R; Haverkos, HW; Kamerer, D; Yu, VL, 1982
)
3.15
"Moxalactam appears to be a potent broad spectrum antibiotic with a low degree of toxicity to rabbit retinal tissue."( Moxalactam (Moxam) in the treatment of experimental staphylococcal endophthalmitis.
House, B; Leeds, NH; Peyman, GA, 1982
)
2.43
"Moxalactam is a beta-lactamase inactivator and inactivates most of the cephalosporinases produced by gram-negative bacteria."( Moxalactam: an oxa-beta-lactam antibiotic that inactivates beta-lactamases.
Labia, R,
)
2.3
"Moxalactam is a synthetically derived, structurally unique beta-lactam antibiotic."( Evaluation of moxalactam.
Aronoff, SC; Bertino, JS; Blumer, JL; Reed, MD; Speck, WT,
)
1.21
"Moxalactam is a newer beta-lactam antibiotic with increased activity and an extended antimicrobial spectrum. "( Moxalactam versus cefazolin prophylaxis for vaginal hysterectomy.
Bawdon, R; Heard, M; Hemsell, D; Hemsell, P; Nobles, B, 1983
)
3.15
"Moxalactam (latamoxef) is a new synthetic oxa-beta-lactam antibiotic administered intravenously or intramuscularly. "( Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Avery, GS; Brogden, RN; Carmine, AA; Heel, RC; Romankiewicz, JA; Speight, TM, 1983
)
3.15
"Moxalactam (LY127935) is a new beta-lactam antibiotic which is chemically related to the cephalosporins. "( In vitro studies of moxalactam (LY127935), a new beta-lactam antibiotic with significant activity against gram-negative bacteria.
Alvarez, S; DeMaria, A; Klein, JO; McCabe, WR, 1980
)
2.03
"Moxalactam (6059-S) is a new beta-lactam derivative with a structure markedly different from those of penicillins or cephalosporins. "( Moxalactam (6059-S), a new 1-oxa-beta-lactam: binding affinity for penicillin-binding proteins of Escherichia coli K-12.
Komatsu, Y; Nishikawa, T, 1980
)
3.15
"Moxalactam (LY127935) is a 1-oxa-beta-lactam which was active in vitro against the majority of 128 strains of gram-negative enteric bacilli isolated from meningitis in neonates. "( Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis.
Loock, CA; McCracken, GH; Schaad, UB; Thomas, ML, 1980
)
1.96
"Moxalactam is a new beta-lactam antimicrobial with an extended spectrum. "( Steady-state moxalactam kinetics: comparisons with other cephalosporins.
Diven, W; Garzone, P; Lyon, J; Pasculle, W; Yu, VL; Zuravleff, J, 1981
)
2.07
"Moxalactam is an investigational cephalosporin that attains concentrations in the cerebrospinal fluid that are 15% to 30% of contemporaneous serum concentrations; moreover, it is quite active against many of the enteric gram-negative bacilli."( Successful treatment of gram-negative bacillary meningitis with moxalactam.
Goldstein, E; Hoeprich, PD; Nolan, SM; Olson, DA, 1981
)
1.22
"Moxalactam promises to be an important addition to our therapeutic armamentarium, especially for therapy of gram-negative bacillary infections."( Clinical evaluation of moxalactam.
Avent, CK; Cobbs, CG; Dismukes, WE; Elliott, AM; Livingston, WK, 1981
)
1.29
"Moxalactam is a new synthetic oxa-beta-lactam antibiotic with a broad spectrum of activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria. "( Pulmonary disposition of moxalactam.
Braude, AC; Cohen, RD; Penner, JL; Preston, MA; Rebuck, AS, 1984
)
2.01
"Moxalactam appears to be a safe, effective drug for complicated urinary tract infections caused by susceptible bacteria, including those resistant to gentamicin."( Comparison of moxalactam and gentamicin in the treatment of complicated urinary tract infections.
Giger, DK; Penn, RG; Preheim, LC; Sanders, CC, 1983
)
1.35
"Moxalactam disodium is a new third-generation semisynthetic, broad-spectrum, cephalosporin-like antibiotic for parenteral administration. "( Moxalactam retinal toxicity.
Fett, DR; Silverman, CA; Yoshizumi, MO, 1984
)
3.15

Effects

Moxalactam plus amikacin has a broader in vitro spectrum, is as effective, and is no more toxic than ticarcillin plus amkacin as empiric therapy for febrile granulocytopenic cancer patients.

Moxalactam has a spectrum of activity that includes both gram positive and gram negative bacteria. It has little, if any, interactions with penicillinases, as is also the case of cefoxitin, cefuroxime and cefotaxime.

ExcerptReferenceRelevance
"Moxalactam plus amikacin has a broader in vitro spectrum, is as effective, and is no more toxic than ticarcillin plus amikacin as empiric therapy for febrile granulocytopenic cancer patients."( Empiric antibiotic therapy for suspected infection in granulocytopenic cancer patients: a comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin.
De Jongh, CA; Finley, RS; Fortner, CL; Moody, MR; Newman, KA; Salvatore, PC; Schimpff, SC; Standiford, HC; Wade, JC; Wiernik, PH, 1982
)
1.19
"Moxalactam has a spectrum of activity that includes both gram positive and gram negative bacteria."( A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.
Fitzpatrick, BJ; Standiford, HC,
)
1.15
"Moxalactam plus amikacin has a broader in vitro spectrum, is as effective, and is no more toxic than ticarcillin plus amikacin as empiric therapy for febrile granulocytopenic cancer patients."( Empiric antibiotic therapy for suspected infection in granulocytopenic cancer patients: a comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin.
De Jongh, CA; Finley, RS; Fortner, CL; Moody, MR; Newman, KA; Salvatore, PC; Schimpff, SC; Standiford, HC; Wade, JC; Wiernik, PH, 1982
)
1.19
"Moxalactam has three other structural elements that affect biologic activity: the methyltetrazolethio moiety, which maximizes in vitro activity; the 7-alpha-methoxy substituent, which confers beta-lactamase stability; and the p-hydroxyphenylmalonyl group, which positively influences not only beta-lactamase stability and the antibacterial spectrum of moxalactam, but also its pharmacokinetics, and leads to a long half-life without high serum binding."( Moxalactam: the first of a new class of beta-lactam antibiotics.
Webber, JA; Yoshida, T,
)
2.3
"Moxalactam has a spectrum of activity that includes both gram positive and gram negative bacteria."( A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.
Fitzpatrick, BJ; Standiford, HC,
)
1.15
"Moxalactam has little, if any, interactions with penicillinases, as is also the case of cefoxitin, cefuroxime and cefotaxime."( [Moxalactam: an inactivator of beta-lactamases].
Labia, R, 1983
)
1.9
"Moxalactam has moderate activity against Pseudomonas aeruginosa, but on the basis of present evidence can not be recommended as sole antibiotic treatment of known or suspected pseudomonal infections."( Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Avery, GS; Brogden, RN; Carmine, AA; Heel, RC; Romankiewicz, JA; Speight, TM, 1983
)
2.43

Treatment

Moxalactam-treated patients had a higher incidence of reversible hepatic enzyme elevation (36%) and Streptococcus faecalis superinfections (12.2%) Two patients with subsequent PT/PTT prolongation had individual clotting factors assayed before and at the time of detection of the abnormal PT.

ExcerptReferenceRelevance
"Moxalactam-treated patients had a higher incidence of reversible hepatic enzyme elevation (36%) and Streptococcus faecalis superinfections (12.2%)."( Randomized comparative study of moxalactam and cefazolin in the treatment of acute urinary tract infections in adults.
Gentry, LO; Lea, AS; Sudan, AW; Wood, BA, 1982
)
1.27
"Two moxalactam-treated patients with subsequent PT/PTT prolongation had individual clotting factors assayed before moxalactam treatment and at the time of detection of the abnormal PT."( Clinical risk factors for prolonged PT/PTT in abdominal sepsis patients treated with moxalactam or tobramycin plus clindamycin.
Baxter, JG; Marble, DA; Schentag, JJ; Walczak, P; Wels, PB; Whitfield, LR, 1985
)
0.97

Toxicity

ExcerptReferenceRelevance
" Adverse reactions occurred in one of 45 ceftizoxime-treated patients, one of 43 cefotaxime-treated patients, and seven of 47 latamoxef-treated patients."( Comparative efficacy and safety of ceftizoxime, cefotaxime and latamoxef in the treatment of bacterial pneumonia in high risk patients.
Baird, I; Bermudez, R; Lorber, B; Noble, R; Silverblatt, F; Vasquez, G; Yangco, BG, 1987
)
0.27
" Studies of reproduction in rats, mice, and rabbits indicated that moxalactam had no teratogenicity and no adverse effects on fertility of parental animals and on gestation or growth and reproductive capacity of offspring."( An evaluation of the toxicity of moxalactam in laboratory animals.
Harada, Y; Hasegawa, Y; Kobayashi, F; Morton, DM; Muraoka, Y; Wold, JS,
)
0.65
" The incidence of adverse reactions was low."( Moxalactam: clinical summary of efficacy and safety.
Kammer, RB,
)
1.57
" All dogs of the 6059-S treated groups survived throughout the experimental period without showing any toxic signs other than occasional vomiting."( [Chronic toxicity study of latamoxef in beagle dog (author's transl)].
Harada, Y; Muraoka, Y; Nara, H; Yoshizaki, T, 1982
)
0.26
"25 mg or less there was no toxic damage to the retina."( Moxalactam retinal toxicity.
Fett, DR; Silverman, CA; Yoshizumi, MO, 1984
)
1.71

Pharmacokinetics

Moxalactam is a new beta-lactam antibiotic. It has high serum concentrations, prolonged half-life and good diffusion. In rabbit CSF, it had the greatest concentration and penetration.

ExcerptReferenceRelevance
" LMOX disappeared from plasma in a monoexponential manner with a half-life of 43 min after intravenous administration at a dose of 50 mg/kg."( Ocular pharmacokinetics of latamoxef and cefaclor in rabbits. Penetration into aqueous humor.
Arai, S; Fukuchi, H; Kimura, M; Kitaura, T; Miyake, K; Tsukiai, S, 1988
)
0.27
" These results indicate that the development of disulfiram-like effects of NMTT-containing antibiotics is closely related to the pharmacokinetic profile of NMTT released from its parent drugs."( Pharmacokinetics of latamoxef and N-methyltetrazolethiol in rats associated with the development of disulfiram-like effects.
Matsubara, T; Ogawa, A; Oka, T; Otsubo, S, 1987
)
0.27
" Cmax was the highest in oviduct (46."( [Pharmacokinetic and clinical studies on latamoxef in the field of obstetrics and gynecology].
Chida, S; Oikawa, N; Sato, M; Shindo, K; Tsuburaya, T, 1987
)
0.27
" Most pharmacokinetic parameters were also significantly altered early in the puerperium relative to those obtained 4 months later."( Pharmacokinetics of cefotaxime, moxalactam, and cefoperazone in the early puerperium.
Charles, D; Larsen, B, 1986
)
0.55
"A novel pharmacokinetic method was developed for analysing the behaviour of a drug in tissues."( A novel pharmacokinetic method for analysis of placental transfer of latamoxef in humans.
Kanao, M; Oguma, T; Okada, H; Yamada, H; Yamamoto, T; Yasuda, J,
)
0.13
" The elimination half-life of both agents was about two to five times longer in pleural fluid than in serum."( Penetration and clearance of cefoperazone and moxalactam in pleural fluid.
Iida, K; Iwanaga, T; Nakanishi, H; Yamada, H; Yamaguchi, M, 1985
)
0.53
" The pharmacokinetic profile showed serum levels sufficient to provide good antimicrobial activity throughout the dosing interval."( Moxalactam and piperacillin: a study of in vitro characteristics and pharmacokinetics in cancer patients.
de Jongh, C; Drusano, GL; Joshi, J; Moody, MR; Newman, K; Schimpff, SC; Wharton, R,
)
1.57
" The mean elimination half-life was 91."( Clinical and pharmacokinetic evaluation of parenteral moxalactam in infants and children.
Feldman, WE; Hollins, M; Keyserling, H; Manning, N; Moffitt, S, 1982
)
0.51
" Pharmacokinetic studies revealed high concentrations of moxalactam in the bile after intravenous administration."( Pharmacokinetics and clinical efficacy of moxalactam in biliary tract infections.
Fabricius, K; Krueger, E; Mueller, O; Rueckert, U,
)
0.64
" In rabbit CSF, moxalactam had the greatest concentration and penetration, but rocephin had the longest half-life and duration of bactericidal activity."( Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis.
Loock, CA; McCracken, GH; Schaad, UB; Thomas, ML, 1981
)
0.87
"The pharmacokinetic parameters of moxalactam were compared with those of cefoperazone and cefotaxime in normal volunteers in a crossover manner."( Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers.
Drusano, GL; McNamee, WB; Ryan, PA; Schimpff, SC; Standiford, HC; Tatem, B,
)
0.69
" Relevant pharmacokinetic parameters were calculated, using two- and three-compartment models."( Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.
Belmega, G; Borner, K; Jendroschek, T; Kemmerich, B; Koeppe, P; Lode, H, 1983
)
0.51
"Specific characteristics of Moxalactam, a new beta-lactam antibiotic, are high serum concentrations, prolonged half-life and good tissular diffusion."( [Pharmacokinetics of moxalactam in adults].
Fillastre, JP; Humbert, G; Leroy, A, 1983
)
0.88
" The consequences of the pharmacokinetic differences between cefotaxim and Moxalactam are exemplified by the comparison of dosage regimens capable of generating and maintaining equivalent concentrations in the various body fluids."( [Comparative pharmacokinetics of moxalactam and other cephalosporins].
Brisson, AM; Fourtillan, JB, 1983
)
0.78
" After a single 1-g intravenous bolus injection, moxalactam elimination half-life was 18."( Moxalactam pharmacokinetics during hemodialysis.
Aronoff, GR; Kleit, SA; Luft, FC; Mong, SA; Sloan, RS, 1981
)
1.96
" A two-compartment model was found to adequately characterize the data, and the serum concentration curve for each drug when given alone was statistically identical to that obtained after simultaneous administration."( Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion.
Kline, BJ; Markowitz, SM; Polk, RE, 1981
)
0.62
" Thus, it is seen that the half-life of both dosages decreased as the infants became older."( [Pharmacokinetic and clinical studies of latamoxef (moxalactam) in neonates and premature infants].
Fujii, R; Hashira, S; Maruyama, S; Oka, T; Sanae, N; Sunakawa, K; Takimoto, M; Tojo, M; Tsuchida, A; Yoshioka, H, 1984
)
0.52
"A pharmacokinetic evaluation of moxalactam was performed with 30 infants and children with documented or suspected bacterial infections arising outside the central nervous system."( Developmental pharmacokinetics of moxalactam.
Aronoff, SC; Bertino, JS; Blumer, JL; Husak, MP; Myers, CM; Reed, MD, 1983
)
0.83
"The authors have carried out the pharmacokinetic and clinical studies of latamoxef (LMOX) in mature and premature neonates."( [Pharmacokinetic and clinical studies of latamoxef in newborn and premature infants].
Nishimura, T; Tabuki, K; Takashima, T, 1983
)
0.27
"The capabilities of two pharmacokinetic amikacin dosing methods were evaluated and compared with the standard amikacin dosage recommended by the manufacturer."( Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients.
Britten, J; Caplan, E; deJongh, CA; Finley, RS; Fortner, CL; Newman, KA; Schimpff, SC; Wade, JC; Wiernik, PH, 1982
)
0.26
"1 liters, respectively), to the terminal half-life (1."( Comparative pharmacokinetics of ceftazidime and moxalactam.
De Schepper, PJ; Mullie, A; Tjandramaga, TB; Van Hecken, A; Verbesselt, R; Verbist, L, 1982
)
0.52
" Additionally, a physiologically based pharmacokinetic model shows that the epimerization of moxalactam after administration in dogs is simulated by the epimerization in serum."( Epimerization of moxalactam by albumin and simulation of in vivo epimerization by a physiologically based pharmacokinetic model.
Hirano, K; Ichihashi, T; Kinoshita, H; Oguma, T; Yamada, H; Yoshikawa, T, 1999
)
0.86
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

The activities of moxalactam and cefotaxime, alone and combined with ampicillin or penicillin, against 40 isolates of group B streptococci were assessed by using the microtiter broth dilution, checkerboard, and time-kill techniques.

ExcerptReferenceRelevance
"Effects of tobramycin (TOB) alone and in combination with latamoxef (LMOX) on the stability of rat kidney lysosomal membranes were investigated."( Studies on the nephrotoxicity of aminoglycoside antibiotics and protection from these effects (4). Effects of tobramycin alone and in combination with latamoxef on the stability of rat kidney lysosomal membranes.
Ito, M; Kojima, R; Suzuki, Y, 1987
)
0.27
"The in vitro effect of latamoxef against 50 clinical strains of Pseudomonas aeruginosa was compared to that of ticarcillin, both alone and in combination with the aminoglycosides gentamicin, tobramycin and amikacin."( Latamoxef in combination with aminoglycosides against Pseudomonas aeruginosa: similarity with ticarcillin.
Sears, SD; Standiford, HC; Tatem, BA, 1985
)
0.27
"The bactericidal activity of moxalactam, alone and in combination with gentamicin, was studied with macrobroth two-dimensional checkerboard and killing curve techniques against gentamicin-resistant and -susceptible strains of Pseudomonas aeruginosa."( Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa.
Edson, RS; Hermans, PE; Washington, JA; Yu, PK, 1983
)
0.82
"The activities of moxalactam and cefotaxime, alone and combined with ampicillin or penicillin, against 40 isolates of group B streptococci were assessed by using the microtiter broth dilution, checkerboard, and time-kill techniques."( Activity of moxalactam and cefotaxime alone and in combination with ampicillin or penicillin against group B streptococci.
Cherubin, CE; Corrado, ML; Landesman, SH; Sierra, MF, 1981
)
0.98
"A broth dilution checkerboard synergy assay was used to assess the activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, in combination with tobramycin, against 38 strains of Pseudomonas aeruginosa."( Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa.
Drew, WL; Mintz, L, 1981
)
0.72

Bioavailability

ExcerptReferenceRelevance
" The estimated bioavailability ranged from 69."( Pharmacokinetics of single-dose administration of moxalactam in unweaned calves.
Soback, S, 1989
)
0.53
" Although the reports prepared by the DICs and pharmacies contained the same amount of information, the DIC-prepared reports included data more frequently on supply sources, therapeutic indications, approved labeling, comparison with established treatment, bioavailability and pharmacokinetics, and recommendations."( Evaluation of pharmacy and therapeutics committee drug evaluation reports.
Johnson, MH; Longe, RL; Majercik, PL; May, JR, 1985
)
0.27
" Rapid and complete intramuscular bioavailability was demonstrated in a subgroup of the study population."( Pharmacokinetics of moxalactam in elderly subjects.
Andritz, MH; Baltch, AL; Conroy, JV; Griffin, PE; Hammer, MC; Smith, RP; Sutphen, N, 1984
)
0.59
" The bioavailability of the antibiotics after administration by either route was almost complete."( Comparative pharmacokinetics of ceftazidime and moxalactam.
De Schepper, PJ; Mullie, A; Tjandramaga, TB; Van Hecken, A; Verbesselt, R; Verbist, L, 1982
)
0.52
"The utilization of the membrane transport protein PEPT1 as a drug delivery system is a promising strategy to enhance the oral bioavailability of drugs."( Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I, 2005
)
0.33

Dosage Studied

Moxalactam given initially as a dosage of 6 g daily is effective for treatment of women with pelvic infections after cesarean delivery. When administered to five normal male volunteers, the antibiotic did not affect the levels of vitamin K-dependent clotting factors II, VII, IX, and X.

ExcerptRelevanceReference
" Microtiter checkerboard technique was compared with standard killing curve method and with killing curves obtained in kinetic in vitro models mimicking single or multiple dosing regimens according to human pharmacokinetics."( Interactions of antimicrobial combinations in vitro: the relativity of synergism.
Blaser, J, 1990
)
0.28
" Twelve-hourly dosing with cefotetan appears to be as effective and well tolerated in regional peritonitis as treatment with shorter-acting agents."( Cephalosporin therapy in intra-abdominal infection: comparative studies of cefotetan, latamoxef and cefoxitin.
Wilson, SE, 1988
)
0.27
" Large doses of latamoxef given at long intervals may be more effective than intermittent dosing or continuous infusion."( Influence of three modes of administration on the penetration of latamoxef into interstitial fluid and fibrin clots and its in-vivo activity against Haemophilus influenzae.
Bergeron, MG; Simard, P, 1986
)
0.27
" In this era of Diagnosis Related Groups and cost containment, the twice-daily dosage schedule of cefotetan is a decided cost benefit."( Cefotetan in the treatment of obstetric and gynecologic infections.
Poindexter, AN; Ritter, M; Sweet, R, 1986
)
0.27
" We conclude that an intravenous dosage of latamoxef (0."( The concentration of latamoxef achieved in the bile and gallbladder wall of patients with cholecystitis.
Fowler, B; Kester, RC; Ramsden, CH; Stewart, J; Vowden, P, 1986
)
0.27
" Dosage for both antibiotic groups was 1 gram given intravenously or intramuscularly on call to the operating room followed by two 1 gram doses at six and 12 hours after the first dose."( Controlled, comparative study of moxalactam and cefazolin for prophylaxis of abdominal hysterectomy.
Berkeley, AS; Freedman, KS; Hayworth, SD; Hirsch, JC; Ledger, WJ, 1985
)
0.55
" More frequent (6 to 8 h) or higher (greater than or equal to 2 g) dosing appears to be necessary to achieve prolonged serum bactericidal activity against less susceptible isolates (MBC, greater than or equal to 2 to 8 micrograms/ml)."( Assessment of serum bactericidal activity after administration of cefoperazone, cefotaxime, ceftizoxime, and moxalactam to healthy subjects.
Barriere, SL; Mordenti, J; Ozasa, DC, 1985
)
0.48
" This method may allow a more rational selection of dosage regimens and drug combinations for the treatment of infections."( Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve.
Barriere, SL; Ely, E; Gambertoglio, JG; Kapusnik, JE, 1985
)
0.27
" The concentration of latamoxef in umbilical cord blood peaked about 2 hours after dosing then decreased in parallel with the maternal blood concentration."( A novel pharmacokinetic method for analysis of placental transfer of latamoxef in humans.
Kanao, M; Oguma, T; Okada, H; Yamada, H; Yamamoto, T; Yasuda, J,
)
0.13
" The pharmacokinetic profile showed serum levels sufficient to provide good antimicrobial activity throughout the dosing interval."( Moxalactam and piperacillin: a study of in vitro characteristics and pharmacokinetics in cancer patients.
de Jongh, C; Drusano, GL; Joshi, J; Moody, MR; Newman, K; Schimpff, SC; Wharton, R,
)
1.57
" Moxalactam disodium, at a dosage of 9 g/day, may be useful for serious Pseudomonas ear infections, including those refractory to other antibiotic therapy."( Moxalactam therapy. Its use in chronic suppurative otitis media and malignant external otitis.
Caparosa, R; Haverkos, HW; Kamerer, D; Yu, VL, 1982
)
2.62
" These data indicate that this dosage of moxalactam is a safe and effective treatment for bacterial infections outside the central nervous system."( Clinical and pharmacokinetic evaluation of parenteral moxalactam in infants and children.
Feldman, WE; Hollins, M; Keyserling, H; Manning, N; Moffitt, S, 1982
)
0.78
"Twenty-patients (14 with mechanical ventilation) received moxalactam in an intensive care unit for pneumonia (3 cases), empyema (5 cases), bronchopneumonia (8 cases), bronchopneumonia with bacteremia (4 cases), 23 organism were isolated and 16 were hospital-acquired: Staphylococcus (3), Escherichia coli (1), Klebsiella-Enterobacter-Serratia (5), Proteus (3), Aeruginosa (2), Acinetobacter (2), These patients received moxalactam at the dosage of 500 mg/8H, 5 at 1 g/12H and 13 at 1 g/8H."( [Use of moxalactam in intensive care units: clinical and bacteriological results related to serum and bronchial concentrations ].
Beaucaire, G; Caillaux, M; Deboscker, Y; Fourrier, A; Mouton, Y, 1982
)
0.94
" The pharmacokinetics parameters of moxalactam when administered intravenously or intramuscularly in single and multiple doses clearly show the kinetics of moxalactam are linear over the dosage ranges studied and are independent of dose."( Single- and multiple-dose pharmacokinetics of moxalactam in normal subjects.
Black, HR; Brier, GL; DeSante, KA; Israel, KS; Wolny, JD, 1982
)
0.8
" Treatment-related effects were limited to soft stool, cecal dilatation, and slight anemia resulting from local injury at the injection site in the higher dosage groups."( An evaluation of the toxicity of moxalactam in laboratory animals.
Harada, Y; Hasegawa, Y; Kobayashi, F; Morton, DM; Muraoka, Y; Wold, JS,
)
0.41
" Thus, moxalactam given initially as a dosage of 6 g daily is effective for treatment of women with pelvic infections after cesarean delivery."( Moxalactam for treatment of pelvic infections after cesarean delivery.
Cunningham, FG; Gibbs, RS; Hemsell, DL,
)
2.03
" Mean daily dosage was 46."( [Treatment of septicemia with latamoxef. Multicentric study of 60 cases].
Armengaud, M; Aubertin, J; Bertrand, A; Carbon, C; Dureux, JB; Gouin, F; Goulon, M; Leng, B; Motin, J; Mouton, Y; Portier, H; Salord, JC; Veyssier, P, 1982
)
0.26
" A recommended dosage schedule is proposed on the basis of moxalactam kinetics during CAPD."( Moxalactam kinetics during chronic ambulatory peritoneal dialysis.
Boutron, HF; Brocard, JF; Fries, D; Merdjan, H; Pocheville, M; Singlas, E, 1983
)
1.95
"The mechanism of action, antibacterial spectrum, pharmacokinetics, current dosage recommendations, adverse reactions, therapeutic uses, and pharmaceutical considerations of moxalactam disodium are reviewed."( Evaluation of moxalactam.
Aronoff, SC; Bertino, JS; Blumer, JL; Reed, MD; Speck, WT,
)
0.69
" Without surgical drainage or therapeutic aspiration, institution of appropriate antibiotic therapy in optimum dosage resulted in complete resolution."( Enterococcal liver abscess associated with moxalactam therapy. Review of literature on enterococcal superinfections in association with moxalactam therapy.
Berk, SL; Thomas, CT; Thomas, E, 1983
)
0.53
" From the collation of bacteriologic and pharmacokinetic data, dosage regimens adjusted to the renal function can be proposed."( [Pharmacokinetics of moxalactam in adults].
Fillastre, JP; Humbert, G; Leroy, A, 1983
)
0.58
" The consequences of the pharmacokinetic differences between cefotaxim and Moxalactam are exemplified by the comparison of dosage regimens capable of generating and maintaining equivalent concentrations in the various body fluids."( [Comparative pharmacokinetics of moxalactam and other cephalosporins].
Brisson, AM; Fourtillan, JB, 1983
)
0.78
" We conclude that Moxalactam is very effective in severe lower respiratory tract infections, with a daily dosage of 30 mg/kg."( [The French experience with moxalactam in pneumology].
Coomans, D; Imbert, Y; Leng, B, 1983
)
0.89
" Both the duration of time cefotaxime was above the MIC90 for the Enterobacteriaceae and the area under the concentration-time curve were significantly less because of its short elimination half-life, results indicating the need for more frequent dosing with cefotaxime than with moxalactam."( Integration of selected pharmacologic and microbiologic properties of three new beta-lactam antibiotics: a hypothesis for rational comparison.
Drusano, GL; Moody, MR; Ryan, PA; Schimpff, SC; Standiford, HC,
)
0.31
" A dosage schedule for administering moxalactam to patients with various degrees of renal dysfunction is provided."( Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.
Bolton, WK; Overby, TL; Sande, MA; Scheld, WM; Spyker, DA, 1980
)
0.86
" Recommendations are given for dosage adjustment in patients with renal insufficiency."( Pharmacokinetics of moxalactam in patients with renal insufficiency.
Czerwinski, AW; Lam, M; Manion, CV, 1981
)
0.59
"To establish dosage recommendations, moxalactam elimination kinetics were studied in six anephric patients during hemodialysis and in four anephric patients during the interdialytic period."( Moxalactam pharmacokinetics during hemodialysis.
Aronoff, GR; Kleit, SA; Luft, FC; Mong, SA; Sloan, RS, 1981
)
1.98
" Dosage schedules were established, adapted to the degree of renal impairment."( Pharmacokinetics of moxalactam in subjects with normal and impaired renal function.
Fillastre, JP; Humbert, G; Leroy, A, 1981
)
0.59
" To establish dosage recommendations, the kinetics of moxalactam elimination were studied in 20 patients with various degrees of renal dysfunction."( Pharmacokinetics of moxalactam in patients with normal and impaired renal function.
Aronoff, GR; Luft, FC; Sloan, RS, 1982
)
0.84
" Although slight elevation of BUN and creatinine in plasma and hyaline casts in lumen of the distal tubules were observed in animals receiving 2,000 mg/kg of LMOX or CET when dosed with FUR, no histological changes were found in renal tissues."( [Comparative nephrotoxicity of latamoxef and other cephalosporins in rabbits. Combined administration with furosemide or tobramycin. (author's transl)].
Harada, Y; Okamoto, T; Teshima, K, 1981
)
0.26
" The serum concentration of LMOX showed a dose-response to the 10 and 20 mg/kg doses in each of the 0--3 day-old group, 4--7 day-old group and 8--28 day-old group."( [Pharmacokinetic and clinical studies of latamoxef (moxalactam) in neonates and premature infants].
Fujii, R; Hashira, S; Maruyama, S; Oka, T; Sanae, N; Sunakawa, K; Takimoto, M; Tojo, M; Tsuchida, A; Yoshioka, H, 1984
)
0.52
" Dosing proposals are given in tabular form."( On the pharmacokinetics of latamoxef in normal and impaired renal function.
Höffler, D; Koeppe, P; Moecke, D, 1984
)
0.27
" Total dosage of lamoxactam administered by patient ranged from 24 to 234 g (mean 57."( Evaluation of lamoxactam in the treatment of severe bacterial infections.
Bouza, E; Guerrero, A; Hospital, JS; Loza, E; Martínez-Beltrán, J; Pérez del Rio, J; Rodríguez-Creixems, M, 1983
)
0.27
" Age-dependent changes in moxalactam elimination were observed for children of less than or equal to 1 year of age, suggesting that a dosage reduction may be necessary for children of less than or equal to 2 months of age."( Developmental pharmacokinetics of moxalactam.
Aronoff, SC; Bertino, JS; Blumer, JL; Husak, MP; Myers, CM; Reed, MD, 1983
)
0.85
" Most systemic infections will permit eight hourly dosing with 500 mg im or iv."( Latamoxef (moxalactam) kinetics in volunteers studied by a specific HPLC assay technique.
Coleman, DL; Hardin, TC; Ludden, TM; Miner, DJ; Shepherd, AM, 1983
)
0.66
" Dosage was 30 to 75 mg/kg per day."( [Clinical effect of latamoxef on newborn and premature infants].
Maruyama, S; Oka, T; Sanae, N; Takimoto, M; Tsuchida, A; Yoshioka, H, 1983
)
0.27
" The serum mean levels at 6 hours after dosage were 12."( [Pharmacokinetic and clinical studies of latamoxef in newborn and premature infants].
Nishimura, T; Tabuki, K; Takashima, T, 1983
)
0.27
" In a very low-birth-weight infant, weighing only 978 g at the time of birth, the serum concentration on the 3rd day after birth was 94 micrograms/ml, while it was found to be 100 micrograms/ml when the dosing and determination were performed on the 37th day after birth."( [Evaluation of latamoxef in the treatment of infections of newborn infants].
Haruta, T; Kobayashi, Y; Kuroki, S; Okura, K, 1983
)
0.27
" In addition, 17 patients, consisting of newborns, immature infants and suckling infants, aged 0 days to 2 months and diagnosed as having various bacterial infections, were also treated with LMOX; the mean daily dosage was 103 mg/kg, administered in 2 to 6 divided doses as one-shot intravenous injections for an average duration of 11 days."( [Experimental and clinical evaluation of latamoxef in newborn and premature infants].
Fujimoto, T; Ishimoto, K; Koga, T; Motohiro, T; Nishiyama, T; Sakata, Y; Shimada, Y; Tanaka, K; Tominaga, K; Tomita, N, 1983
)
0.27
" Fifteen patients, consisting of 8 cases of catarrhal appendicitis and 7 cases of gangrenous appendicitis, were administered LMOX at 50 mg/kg/day, while 13 patients with peritonitis due to a perforated appendix were treated with a dosage of 90 mg/kg/day."( [Postoperative chemotherapy of perforating appendicitis in children; with special reference to latamoxef therapy].
Iida, H; Inoue, I; Ito, F; Koda, S; Takizawa, J; Yamamori, H, 1983
)
0.27
"The capabilities of two pharmacokinetic amikacin dosing methods were evaluated and compared with the standard amikacin dosage recommended by the manufacturer."( Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients.
Britten, J; Caplan, E; deJongh, CA; Finley, RS; Fortner, CL; Newman, KA; Schimpff, SC; Wade, JC; Wiernik, PH, 1982
)
0.26
" The convenient once daily dosage schedule combined with fewer severe adverse reactions favours the use of ceftriaxone instead of latamoxef."( Ceftriaxone versus latamoxef in febrile neutropenic patients: empirical monotherapy in patients with solid tumours.
Boas, J; Bruun, BG; Dombernowsky, P; Frimodt-Møller, N; Hansen, HH; Hansen, OP; Holländer, NH; Oturai, PS, 1993
)
0.29
" In this study, the antibacterial activity of LMOX was investigated, and Monte Carlo simulation was conducted to determine the appropriate dosing regimens of LMOX against extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae."( Potent antibacterial activities of latamoxef (moxalactam) against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation.
Ito, A; Nakamura, R; Tatsumi, Y; Tsuji, M; Wajima, T, 2014
)
0.66
" Latamoxef, a semi-synthetic oxacephem antibiotic developed in 1980s, has recently been brought back into use for treatment of infections in newborns; however, it is still used off-label in neonatal clinical practice due to the lack of an evidence-based dosing regimen."( Population pharmacokinetics and dosing optimization of latamoxef in neonates and young infants.
Chen, XK; Dong, Q; Guo, YJ; Jin, F; Kou, C; Luo, XJ; Qi, H; Qi, X; Qi, YJ; Shen, AD; Shen, YH; Shi, HY; Tang, BH; Wang, YC; Wu, YE; Zhao, W; Zheng, Y, 2019
)
0.51
" Simulation indicated that the current dosing regimen (30 mg/kg q12h) is adequate with an MIC of 1 mg/L."( Population pharmacokinetics and dosing optimization of latamoxef in neonates and young infants.
Chen, XK; Dong, Q; Guo, YJ; Jin, F; Kou, C; Luo, XJ; Qi, H; Qi, X; Qi, YJ; Shen, AD; Shen, YH; Shi, HY; Tang, BH; Wang, YC; Wu, YE; Zhao, W; Zheng, Y, 2019
)
0.51
"Based on the developmental PK-PD analysis of latamoxef, a rational dosing regimen of 30 mg/kg q12h or q8h was required in newborns, depending on the pathogen."( Population pharmacokinetics and dosing optimization of latamoxef in neonates and young infants.
Chen, XK; Dong, Q; Guo, YJ; Jin, F; Kou, C; Luo, XJ; Qi, H; Qi, X; Qi, YJ; Shen, AD; Shen, YH; Shi, HY; Tang, BH; Wang, YC; Wu, YE; Zhao, W; Zheng, Y, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
oxacephemAny member of the oxacephem sub-group of cephem antibiotics, in which the thiaazabicyclo moiety of the cephalosporins is replaced by an oxaazabicyclo moiety, and where R3 is -H or -OCH3.
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 15 member 1Homo sapiens (human)Ki12,150.00000.18003.39339.8000AID238858; AID681115
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki87.00003.00006.47788.5000AID681114
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase class B VIM-2 Pseudomonas aeruginosaKm55.00002.00006.65009.4000AID531315
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (85)

Assay IDTitleYearJournalArticle
AID534382Antibacterial activity against Escherichia coli K-12 W1895 transconjugant harboring pCF243 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID495797Activity at Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B carrying pSau12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID534394Activity of Beta-lactamase KHM-1 in Escherichia coli JM109 harboring recombinant pKHM-1 assessed as compound hydrolysis by UV-visible spectrophotometry2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID1211806Drug excretion in Sprague-Dawley rat assessed as compound excreted into bile at 300 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID520876Antibacterial activity against Achromobacter xylosoxidans CIP69598 by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID534391Antibacterial activity against Escherichia coli JM109 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID495793Antimicrobial activity against Escherichia coli DH10B by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID1211839Total biliary clearance in human at 1 gm, iv after 8 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID531315Activity of Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID529458Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase TEM-1, CTX-M-15 and Oxa-1 by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID681115TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in Caco-2 cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID604023Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID285441Antimicrobial activity against Escherichia coli DH10B after 18 hrs by disk diffusion method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID340738Ratio of Kcat to Km of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis relative to control2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID1209583Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID495798Ratio of Kcat to Km of Pseudomonas fluorescens PF-1 beta-lactamase BIC-1 expressed in Escherichia coli DH10B using nitrocefin hydrolysis2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID584847Ratio of Kcat to Km for Aeromonas allosaccharophila AL-1 beta-lactamase PER62010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID604026Unbound CSF to plasma concentration ratio in human2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID534396Ratio of Kcat to Km for Escherichia coli JM109 harboring recombinant pKHM-1 Beta-lactamase KHM-1 assessed as compound hydrolysis by UV-visible spectrophotometry2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID498872Antimicrobial activity against Acinetobacter baumannii B9 containing carbapenemase blaOXA-23 gene assessed as growth inhibition by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.
AID373209Activity of Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3)2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID531316Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID1211820Drug excretion in human assessed as compound excreted into bile at 1 gm, iv after 8 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID373053Antimicrobial activity against Escherichia coli DH10B by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID373052Antimicrobial activity against Escherichia coli DH10B carrying pJIM2246 expressing Bacillus clausii NR beta-lactamase BCL1 by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID373210Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3)2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID520879Antibacterial activity against Achromobacter xylosoxidans DUC by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID584837Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER1 by agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID529457Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone B expressing beta-lactamase Oxa-48, TEM-1, CTX-M-15 and Oxa-1 by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID584838Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER2 by agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID373211Ratio of Kcat to Km for Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3) relative to benzyl-penicillin2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID373054Antimicrobial activity against Escherichia coli BL21(DE3) carrying pET9a expressing Bacillus clausii beta-lactamase BCL1 by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID534385Antibacterial activity against Escherichia coli K-12 W1895 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID1211882Unbound biliary clearance in Sprague-Dawley rat at 300 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID520878Antibacterial activity against Achromobacter xylosoxidans LOL by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID1209581Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID584846Activity at Aeromonas allosaccharophila AL-1 beta-lactamase PER62010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID340736Activity of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID531313Activity of Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID520881Antibacterial activity against Escherichia coli TOP10 harboring recombinant p6S3 expressing beta lactamase OXA-114a by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID534379Antibacterial activity against Citrobacter freundii KHM243 clinical isolate by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID520880Antibacterial activity against Achromobacter xylosoxidans TB1 by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID681114TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in SKPT cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID520877Antibacterial activity against Achromobacter xylosoxidans MER by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID1211888Total biliary clearance in Sprague-Dawley rat at 300 mg/kg, iv2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID604022Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID604020Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID373055Antimicrobial activity against Escherichia coli BL21(DE3) by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID373051Antimicrobial activity against Bacillus clausii ATCC 21537 by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID1211859Unbound biliary clearance in human at 1 gm, iv after 8 hrs by T-tube method2013Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
AID529456Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone A expressing beta-lactamase Oxa-48, TEM-1, SHV-12 and Oxa-9 by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID1209582Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID584839Antimicrobial activity against Escherichia coli DH10B by agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID495792Antimicrobial activity against Escherichia coli DH10B harbouring recombinant plasmid pSau1 expressing beta-lactamase BIC-1 from Pseudomonas fluorescens PF-1 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID285440Antimicrobial activity against Escherichia coli DH10B expressing GIL1 after 18 hrs by disk diffusion method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID584835Antimicrobial activity against Aeromonas allosaccharophila AL-1 expressing beta-lactamase PER6 by agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID238858Binding affinity against membrane transport protein PEPT1 in human Caco-2 cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
AID520882Antibacterial activity against Escherichia coli TOP10 by agar dilution method2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID495791Antimicrobial activity against Pseudomonas fluorescens isolate PF-1 expressing beta-lactamase BIC-1 by Etest2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
AID529460Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase TEM-1, SHV-12 and Oxa-9 by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID604024Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID534388Antibacterial activity against Escherichia coli JM109 harboring recombinant pKHM-1 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID531318Ratio of Kcat to Km for Escherichia coli beta-lactamase VIM-1 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID529459Antimicrobial activity against Escherichia coli J53 harboring beta-lactamase Oxa-48 by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID584836Antimicrobial activity against Escherichia coli DH10B harboring recombinant Aeromonas allosaccharophila AL-1 beta-lactamase PER6 by agar dilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID531317Activity of Escherichia coli beta-lactamase VIM-1 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID529461Antimicrobial activity against Escherichia coli J53 by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID285439Antimicrobial activity against Citrobacter gillenii CIP 106783 after 18 hrs by disk diffusion method2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Chromosome-encoded narrow-spectrum Ambler class A beta-lactamase GIL-1 from Citrobacter gillenii.
AID38399Binding affinity towards AmpC beta-lactamase binding site from Escherichia coli; NA means not applicable2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Structure-based approach for binding site identification on AmpC beta-lactamase.
AID531314Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID604025Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1209592Dissociation constant, pKa of the basic compound by capillary electrophoresis-mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID373050Antimicrobial activity against Bacillus clausii NR expressing beta-lactamase BCL1 by agar-dilution technique2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID604021Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr b2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (898)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990773 (86.08)18.7374
1990's62 (6.90)18.2507
2000's31 (3.45)29.6817
2010's24 (2.67)24.3611
2020's8 (0.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.01 (24.57)
Research Supply Index7.01 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index59.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials128 (13.02%)5.53%
Reviews26 (2.64%)6.00%
Case Studies96 (9.77%)4.05%
Observational0 (0.00%)0.25%
Other733 (74.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]